BC
ALNY icon

Bartlett & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bartlett & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$19K – 1135
2023
Q2 		$19K Hold
100
– – ﹤0.01% 828
2023
Q1 		$20K Hold
100
– – ﹤0.01% 710
2022
Q4 		$24K Hold
100
– – ﹤0.01% 684
2022
Q3 		$20K Buy
+100
New +$19.1K ﹤0.01% 703

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bartlett & Co's ALNY Position: Q3 2023 in Review

Bartlett & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 100 shares — an estimated $19K sold.

Bartlett & Co first reported a position in ALNY in Q3 2022 and held it in 4 quarters. The position peaked at $24K in Q4 2022. 452 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • Bartlett & Co reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Bartlett & Co sold 100 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $19K.
  • Bartlett & Co first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Bartlett & Co's Alnylam Pharmaceuticals position peaked at $24K in Q4 2022.
  • 452 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Bartlett & Co's 13F filing for Q3 2023, filed 10 Oct 2023.